News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2018 Shelley Wood November 30, 2018
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Daily News Diabetes Drug Canagliflozin Gets MACE Reduction Indication Todd Neale November 01, 2018
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2018 Shelley Wood October 02, 2018
News Conference News ESC 2018 Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm Todd Neale August 27, 2018
News Daily News In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check Caitlin E. Cox August 15, 2018
News Daily News SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function Todd Neale July 02, 2018
News Conference News EAS 2018 Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics Yael L. Maxwell May 16, 2018
News Daily News PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations Michael O'Riordan May 10, 2018
News Conference News CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin Michael O'Riordan March 16, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Daily News Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery Yael L. Maxwell January 09, 2018